Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
2016 ◽
Vol 214
(1)
◽
pp. 99.e1-99.e8
◽
2010 ◽
Vol 203
(2)
◽
pp. 162.e1-162.e8
◽
2011 ◽
Vol 2011
◽
pp. 493-495
Keyword(s):
1996 ◽
Vol 16
(1)
◽
pp. 53-60
◽
Keyword(s):
2004 ◽
Vol 11
(2)
◽
pp. 89-94
◽
2018 ◽
Vol Volume 13
◽
pp. 107-111
◽
Keyword(s):